MedTrace Logo

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia

NCT05192304 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2022-01-14

No results posted yet for this study

Summary

This is a Phase Ib clinical study of TPN672 maleate in patients with schizophrenia

Conditions

Interventions

DRUG

TPN-672

single dose of TPN-672 maleate tablet

Sponsors & Collaborators

  • Shanghai Mental Health Center

    collaborator OTHER

  • Jiangsu Kanion Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Li Huafang, MD PhD · Shanghai Mental Health Center

  • Li Guanjun · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2023-03-01
Completion
2024-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05192304 on ClinicalTrials.gov